There’s growing prove that the smoking-cessation drug Chantix is connected to dangerous “neuropsychiatric” fallouts, such as agitation, depressed mood and even suicide, U.S. health officials said Friday. The U.S. FDA has asked Chantix’s manufacturer, Pfizer Inc., to create the warning about these potential troubles more prominent on prescribing information and on the drug’s label. The authority is also working with Pfizer to produce a Medication Guide for patients, officials said.

“We have become more and more concerned as we have discovered a number of compelling cases that truly appear as if they’re the outcome of exposure to the drug and not to other causes,” Dr. Bob Rappaport, director of the FDA’s Division of Anesthesia, Analgesia and Rheumatology Products, said during an afternoon teleconference.

The FDA knows of 491 cases of suicidal behavior associated with Chantix, said Dr. Celia Winchell, a team leader in the FDA’s Division of Anesthesia, Analgesia and Rheumatology Products. “Of these, 420 are from the America,” Winchell said. “There are 39 that involve completed suicides, 34 in the United States.”

According to Pfizer, five million patients have taken Chantix, whose generic name is varenicline. Friday’s warning follows a Nov. 20 FDA statement that the agency was “evaluating post-marketing adverse event reports on Chantix related to changes in behavior, agitation, depressed mood, suicidal ideation, and actual suicidal behavior.”

Last month, Pfizer agreed, after consulting with the FDA, to update packages of Chantix sold in the United States to more prominently display a warning that users should be monitored for suicidal behavior, depressed mood, and other mental health symptoms. The FDA approved Chantix in May 2006 as a smoking-cessation drug. It acts in areas of the brain affected by nicotine and may ease withdrawal symptoms and block the effects of nicotine if users resume smoking.

On Friday, FDA officials advised patients to tell their doctor about any history of psychiatric illness before starting Chantix. The drug can cause current psychiatric illness to get worse even if it is under control. Chantix may also cause the recurrence of an old psychiatric illness, the officials warned.

Patients should also report changes in mood and behavior to their doctor. Symptoms to look out for include anxiety, nervousness, tension, depressed mood, unusual behaviors and thinking about or attempting suicide, the FDA officials said. In most cases, these symptoms developed while taking Chantix, but they can also appear after stopping the drug, the officials noted.

“We are continuing with the review process over the next several months as we try to pin down to what extent these problems are being seen with Chantix,” Rappaport said. Vivid, unusual, or strange dreams may occur while taking the drug. Patients may also experience impaired ability to drive or operate heavy machinery, the officials said.

via medicinenet

More Interesting Article :

• Knowing Suicide Symptoms
• Anti-Epileptics May Trigger Suicide
• Want More 14 Years For Your Age?
• Sun Lights May Lower Lung cancer Risk
• How to Preventing a Heart Attack